David S. Small

3.3k total citations
66 papers, 2.4k citations indexed

About

David S. Small is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, David S. Small has authored 66 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cardiology and Cardiovascular Medicine, 22 papers in Surgery and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in David S. Small's work include Antiplatelet Therapy and Cardiovascular Diseases (36 papers), Lipoproteins and Cardiovascular Health (20 papers) and Diabetes Treatment and Management (9 papers). David S. Small is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (36 papers), Lipoproteins and Cardiovascular Health (20 papers) and Diabetes Treatment and Management (9 papers). David S. Small collaborates with scholars based in United States, United Kingdom and Sweden. David S. Small's co-authors include Kenneth J. Winters, Christopher D. Payne, Nagy A. Farid, Joseph A. Jakubowski, John T. Brandt, Daniel E. Salazar, Ying G. Li, Govinda Weerakkody, Hideo Naganuma and C. Steven Ernest and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

David S. Small

64 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David S. Small United States	28	1.9k	924	526	382	367	66	2.4k
Young‐Hoon Jeong South Korea	31	2.6k 1.4×	1.4k 1.5×	631 1.2×	253 0.7×	328 0.9×	172	3.2k
Christopher D. Payne United States	29	2.8k 1.5×	1.3k 1.4×	777 1.5×	631 1.7×	635 1.7×	45	3.5k
C. Steven Ernest United States	22	1.4k 0.7×	662 0.7×	311 0.6×	439 1.1×	452 1.2×	41	2.1k
Louis Roy Canada	24	1.7k 0.9×	1.2k 1.3×	438 0.8×	218 0.6×	98 0.3×	67	2.9k
Yongwhi Park South Korea	22	1.2k 0.7×	699 0.8×	265 0.5×	140 0.4×	214 0.6×	108	1.5k
Stéphane Arquès France	18	1.5k 0.8×	607 0.7×	303 0.6×	108 0.3×	161 0.4×	46	2.0k
Francesco Franchi United States	31	2.4k 1.3×	1.2k 1.3×	648 1.2×	156 0.4×	342 0.9×	104	2.8k
Fabiana Rollini United States	29	2.2k 1.2×	1.1k 1.2×	602 1.1×	142 0.4×	315 0.9×	112	2.5k
Rolf P. Kreutz United States	16	984 0.5×	482 0.5×	403 0.8×	132 0.3×	132 0.4×	54	1.4k
Thomas C. Smitherman United States	18	1.7k 0.9×	654 0.7×	314 0.6×	228 0.6×	125 0.3×	46	2.5k

Countries citing papers authored by David S. Small

Since Specialization

Citations

This map shows the geographic impact of David S. Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Small more than expected).

Fields of papers citing papers by David S. Small

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Small. The network helps show where David S. Small may publish in the future.

Co-authorship network of co-authors of David S. Small

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Small. A scholar is included among the top collaborators of David S. Small based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Small. David S. Small is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mendizábal, Nieves Vélez de, et al.. (2021). Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model. Clinical Pharmacokinetics. 61(2). 249–262. 5 indexed citations

Moser, Brian A., Elizabeth LaBell, Emmanuel Chigutsa, Joseph A. Jakubowski, & David S. Small. (2017). Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. Clinical Pharmacokinetics. 57(2). 243–254. 4 indexed citations

Hoppe, Carolyn, Chunmei Zhou, Patricia Brown, et al.. (2016). Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis. 117(3). 580–588. 13 indexed citations

Small, David S., Wei Zhang, Jane Royalty, et al.. (2015). A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State. Journal of Cardiovascular Pharmacology and Therapeutics. 20(5). 483–489. 8 indexed citations

Styles, Lori, Darell Heiselman, Brian A. Moser, et al.. (2014). Prasugrel in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 37(1). 1–9. 20 indexed citations

Yu, Kyung‐Sang, Kyung Woo Park, Ronan P. Kelly, et al.. (2013). Pharmacokinetic and Pharmacodynamic Effects of Prasugrel in Healthy Korean Males. Journal of Cardiovascular Pharmacology. 62(1). 72–77. 7 indexed citations

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. Journal of the American College of Cardiology. 60(20). 2032–2040. 63 indexed citations

Riesmeyer, Jeffrey S., Daniel E. Salazar, Govinda J. Weerakkody, et al.. (2011). Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy. The Journal of Clinical Pharmacology. 52(6). 789–797. 41 indexed citations

Kelly, Ronan P., Sandra Close, Nagy A. Farid, et al.. (2011). Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British Journal of Clinical Pharmacology. 73(1). 93–105. 42 indexed citations

10.

Rohatagi, Shashank, et al.. (2010). Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes. The Journal of Clinical Pharmacology. 50(8). 904–913. 4 indexed citations

11.

Small, David S., Prajakti A. Kothare, Eunice Yuen, et al.. (2009). The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. European Journal of Clinical Pharmacology. 66(2). 127–135. 55 indexed citations

12.

Wrishko, Rebecca E., C. Steven Ernest, David S. Small, et al.. (2009). Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38. The Journal of Clinical Pharmacology. 49(8). 984–998. 66 indexed citations

13.

Small, David S., Nagy A. Farid, Christopher D. Payne, et al.. (2008). Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel. The Journal of Clinical Pharmacology. 48(4). 475–484. 245 indexed citations

14.

Zhang, Lu, Jill Chappell, Celedon Gonzales, et al.. (2007). QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study. Journal of Cardiovascular Pharmacology. 49(3). 146–153. 52 indexed citations

15.

Payne, Christopher D., David S. Small, C. Steven Ernest, et al.. (2007). Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. Journal of Cardiovascular Pharmacology. 50(5). 555–562. 135 indexed citations

16.

Burkey, Jennifer, et al.. (2006). Disposition of [14C]Ruboxistaurin in Humans. Drug Metabolism and Disposition. 34(11). 1909–1917. 9 indexed citations

17.

Small, David S.. (2005). The Global LNG Industry - Changed Market Dynamics. 1 indexed citations

18.

Small, David S., Andrew Acheampong, Brenda L. Reis, et al.. (2002). Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A Ophthalmic Emulsions in Patients With Moderate to Severe Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics. 18(5). 411–418. 39 indexed citations

19.

Acheampong, Andrew, et al.. (2002). Formulation Effects on Ocular Absorption of Brimonidine in Rabbit Eyes. Journal of Ocular Pharmacology and Therapeutics. 18(4). 325–337. 36 indexed citations

20.

Madhu, C, et al.. (1997). Metabolic Deesterification of Tazarotene in Human Blood and Rat and HumanLiver Microsomes. Journal of Pharmaceutical Sciences. 86(8). 972–974. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact